InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,077.13
(
-0.14%
)
Post# of 25232
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

greenehugh

Send PM Follow Ignore
Followers 44
Posts 12394
Boards Moderated 0
Alias Born 03/19/2001

greenehugh

Re: Profit_Ace post# 24240

Tuesday, 10/05/2004 6:27:50 PM

Tuesday, October 05, 2004 6:27:50 PM

Post# of 25232
Your welcome. Here is an informed opinion on Arcoxia posted by DewDiligence in reply to to my question.
>> Any thoughts on the probability of MRK's Arcoxia getting approval? <<
Clearly lower than it was a week ago. The FDA reviewers will now be asking themselves:
1. Do patients really need another Cox-2 inhibitor?
2. If the answer above is Yes, do patients need more than one new one?
3. If the answer above is No, should the addition be Merck’s Arcoxia or Novartis’ Prexige?

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up